Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression
Metadata
Show full item recordAuthor
Toro Domínguez, Daniel; Martorell Marugán, Jordi; Martínez Bueno, Manuel; López Domínguez, Raúl; Carnero Montoro, Elena; Barturen Briñas, Guillermo; Carmona Sáez, Pedro; Alarcón Riquelme, Marta EugeniaEditorial
Oxford University Press
Materia
Systemic lupus erythematosus Autoimmune diseases Computational models Molecular profiling Personalized medicine
Date
2022-08-10Referencia bibliográfica
Daniel Toro-Domínguez... [et al.]. Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression, Briefings in Bioinformatics, Volume 23, Issue 5, September 2022, bbac332, [https://doi.org/10.1093/bib/bbac332]
Sponsorship
PID2020-119032RB-I00 supported by MCIN/AEI/10.13039/501100011033; FEDER and the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR); European Union’s Horizon 2020; EFPIA; FEDER/Junta de Andalucía-Consejer’a de Transformación Económica, Industria, Conocimiento y Universidades (grants P20_00335 and B-CTS-40-UGR20); ‘Consejería de Transformación Económica, Industria, Conocimiento y Universidades’ (CTEICU); European Union through the European Social Fund (ESF) named ‘Andalucía se mueve con Europa”; Andalusian ESF Operational Program 2014–2020; ISCIII CD18/00149; Ministerio de Universidades (Spain’s Government) and the European Union – NextGenerationEUAbstract
Objectives
Systemic Lupus Erythematosus is a complex autoimmune disease that leads to significant worsening of quality of life and mortality. Flares appear unpredictably during the disease course and therapies used are often only partially effective. These challenges are mainly due to the molecular heterogeneity of the disease, and in this context, personalized medicine-based approaches offer major promise. With this work we intended to advance in that direction by developing MyPROSLE, an omic-based analytical workflow for measuring the molecular portrait of individual patients to support clinicians in their therapeutic decisions.
Methods
Immunological gene-modules were used to represent the transcriptome of the patients. A dysregulation score for each gene-module was calculated at the patient level based on averaged z-scores. Almost 6100 Lupus and 750 healthy samples were used to analyze the association among dysregulation scores, clinical manifestations, prognosis, flare and remission events and response to Tabalumab. Machine learning-based classification models were built to predict around 100 different clinical parameters based on personalized dysregulation scores.
Results
MyPROSLE allows to molecularly summarize patients in 206 gene-modules, clustered into nine main lupus signatures. The combination of these modules revealed highly differentiated pathological mechanisms. We found that the dysregulation of certain gene-modules is strongly associated with specific clinical manifestations, the occurrence of relapses or the presence of long-term remission and drug response. Therefore, MyPROSLE may be used to accurately predict these clinical outcomes.
Conclusions
MyPROSLE (https://myprosle.genyo.es) allows molecular characterization of individual Lupus patients and it extracts key molecular information to support more precise therapeutic decisions.